Navepegritide clinical trials
Navepegritide is named as an intervention in 2 current clinical trials in our Ireland, UK, France, Denmark, Canada, USA, Germany, Italy, Sweden, Austria, Norway, Portugal and Australia registers. 1 is recruiting patients now. All registered phases are Phase 2. The lead sponsor is Ascendis Pharma A/S. The most-studied condition is Achondroplasia.
Where Navepegritide is approved
All regulators →Of the three regulators tracked here, the first to approve Navepegritide was the US, on 27 Feb 2026.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Navepegritide patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Navepegritide, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 12 listed patents; the last listed expires 12 Nov 2042 (US 12377133).
- Latest patent on the drug substance itself: 5 Jan 2037 (US 10835578).
- Exclusivity ODE-516: Orphan drug exclusivity: to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses, until 27 Feb 2033.
- Exclusivity NCE: New chemical entity, until 27 Feb 2031.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
How Navepegritide works
All drug targets →- Agonist at NPR2 Primary targetTarget: NPR2 natriuretic peptide receptor 2Guide to Pharmacology only
- AchondroplasiaPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594507, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 14293, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Navepegritide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Navepegritide
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
NCT06079398 · Achondroplasia
|
Phase 2 | Recruiting | Ascendis Pharma A/S | Ireland, UK, USA, Germany, France, Italy, Sweden, Denmark, Austria, Norway, Portugal, Canada, Australia |
|
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
NCT06732895 · Achondroplasia
|
Phase 2 | Active, closed | Ascendis Pharma A/S | Ireland, UK, France, Denmark, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Navepegritide
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Ascendis Pharma A/S | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Navepegritide trials
How many clinical trials are testing Navepegritide?
2 current trials in our Ireland, UK, France, Denmark, Canada, USA, Germany, Italy, Sweden, Austria, Norway, Portugal and Australia registers name Navepegritide as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Navepegritide trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Ireland, 1 with sites in UK, 1 with sites in France, 1 with sites in Denmark, 1 with sites in Canada, 1 with sites in USA, 1 with sites in Germany, 1 with sites in Italy, 1 with sites in Sweden, 1 with sites in Austria, 1 with sites in Norway, 1 with sites in Portugal and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Navepegritide clinical trials?
The lead sponsor is Ascendis Pharma A/S. The number in brackets is how many trials each organisation leads.
Are there Navepegritide clinical trials in Ireland?
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Navepegritide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Navepegritide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Navepegritide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.